Claims
- 1. An amine compound represented by the formula: ##STR567## or pharmaceutically acceptable salt thereof, wherein R.sup.1 is phenyl, thienyl or furyl which may optionally be substituted by at least one substituent selected from the group consisting of C.sub.1-8 alkyl or, ##STR568## wherein R.sup.6 and R.sup.7, which may be the same or different, are C.sub.1-8 alkyl or R.sup.6 and R.sup.7 may be bonded together forming a piperidino radical and A is C.sub.1-4 alkylene; p is 0 or 1; X is oxygen or sulfur; q is 2 or 3; Z is CHNO.sub.2 ; Y is C.sub.1-4 -alkylene; R.sup.2 is phenyl or thienyl which may optionally be substituted by at least one substituent selected from the group consisting of halogen, hydroxyl, amino, C.sub.1-8 alkyl, C.sub.1-4 alkoxy, halogeno-C.sub.1-4 alkyl or methylenedioxy in which the oxygen atoms are linked to adjacent carbon atoms; and R.sup.3 is hydrogen.
- 2. N-{2-[[5-(dimethylamino)methyl-2-furyl]methylthio]ethyl}-N'-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-2-nitro-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 3. N-{2-[[5-(dimethylamino)methyl-2-furyl]methylthio]ethyl}-N'-[2-(3-fluorophenyl)-2-hydroxyethyl]-2-nitro-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 4. N-{2-[[5-(dimethylamino)methyl-2-furyl]methylthio]ethyl}-N'-[2-hydroxy-2-(3-methyl-2-thienyl)ethyl]-2-nitro-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 5. N-{2-[[5-(dimethylamino)methyl-4-methyl-2-thienyl]methylthio]ethyl}-N'-[2-hydroxy-2-(3-methoxyphenyl)ethyl]-2-nitro-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 6. N-[2-(4-fluorophenyl)-2-hydroxyethyl]-2-nitro-N'-[3-(3-piperidinomethylphenoxy)propyl]-1,1-ethenediamine or a pharmacetically acceptable salt thereof.
- 7. N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-2-nitro-N'-[3-(3-piperidinomethylphenoxy)propyl]-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 8. N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-2-nitro-N'-[3-(3-piperidinomethylphenoxy)propyl]-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 9. N-[2-hydroxy-2-(4-methoxyphenyl)ethyl]-2-nitro-N'-[3-(3-piperidinomethylphenoxy)propyl]-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 10. N-[2-(4-chlorophenyl)-2-hydroxyethyl]-2-nitro-N'-[3-(3-piperidinomethylphenoxy)propyl]-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 11. N-[2-(4-aminophenyl)-2-hydroxyethyl]-2-nitro-N'-[3-(3-piperidinomethylphenoxy)propyl]-1,1-ethenediamine of a pharmaceutically acceptable salt thereof.
- 12. N-[2-hydroxy-2-(3,4-methylenedioxyphenyl)ethyl]-2-nitro-N'-[3-(3-piperidinomethylphenoxy)propyl]-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 13. N-[2-hydroxy-2-(3-methyl-2-thienyl)ethyl]-2-nitro-N'-[3-(3-piperidinomethylphenoxy)propyl]-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 14. N-{2-[[5-(dimethylamino)methyl-4-methyl-2-thienyl]methylthio]ethyl}-N'-[2-(4-ethylphenyl)-2-hydroxyethyl]-2-nitro-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 15. N-{2-[[5-(dimethylamino)methyl-2-furyl]methylthio}-N'-{S(+)-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]}-2-nitro-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 16. N-{2-[[5-(dimethylamino)methyl-4-methyl-2-thienyl]methylthio]ethyl}-N'-(.beta.-hydroxyphenethyl)-2-nitro-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 17. N-[2-(3-chlorophenyl)-2-hydroxyethyl]-N'-{2-[[5-(dimethylamino)methyl-4-methyl-2-thienyl]methylthio]ethyl}-2-nitro-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 18. N-[2-(3-bromophenyl)-2-hydroxyethyl]-N'-{2-[[5-(dimethylamino)methyl-4-methyl-2-thienyl]methylthio]ethyl}-2-nitro-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 19. N-{2-[[5-(dimethylamino)methyl-4-methyl-2-thienyl]methylthio]ethyl}-N'-[2-hydroxy-2-(3-methylphenyl)ethyl]-2-nitro-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 20. N-{2-[[5-(dimethylamino)methyl-4-methyl-2-thienyl]methylthio]ethyl}-N'-[2-hydroxy-2-(3-trifluoromethylphenyl)ethyl]-2-nitro-1,1-ethenediamine or a pharmaceutically acceptable salt thereof.
- 21. An anti-ulcer agent, comprising: a pharmaceutically effective amount of the amine compound or a pharmaceutically acceptable salt thereof according to any one of claims 2-14 and 15-20.
- 22. A method for treating mammals including human beings having ulcers, comprising: administering to said mammal a therapeutically effective amount of the amine compound or pharmaceutically acceptable salt thereof according to any one of claims 2-14 and 15-20.
Priority Claims (1)
Number |
Date |
Country |
Kind |
57-198434 |
Nov 1982 |
JPX |
|
Parent Case Info
This is a division of application Ser. No. 550,933, filed Nov. 14, 1983, now U.S. Pat. No. 4,643,849.
US Referenced Citations (6)
Foreign Referenced Citations (2)
Number |
Date |
Country |
53-149936 |
Dec 1978 |
JPX |
54-109963 |
Aug 1979 |
JPX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
550933 |
Nov 1983 |
|